Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Multiple Myeloma Paradigm Moves Forward With Promising Portfolio

June 25th 2020

There was no shortage of exciting developments at the 2020 ASCO Virtual Scientific Program in multiple myeloma. Peter Voorhees, MD, explained all of the pivotal data in myeloma therapeutics in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25th 2020

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Dr. Usmani on Current Challenges in High-Risk Multiple Myeloma

June 25th 2020

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.

Isatuximab-Based Quadruplet Induces 100% ORR, Deep Responses in High-Risk Newly Diagnosed Myeloma

June 25th 2020

The quadruplet regimen of isatuximab-irfc, carfilzomib, lenalidomide, and dexamethasone elicited a 100% overall response rate and high rates of minimal residual disease negativity in high-risk newly diagnosed multiple myeloma.

Berdeja Projects Promising Future for JNJ-4528 in Relapsed/Refractory Myeloma

June 24th 2020

Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.

Dr. Richardson on First-In-Human Phase 1 Trial With CC-92480 in R/R Myeloma

June 23rd 2020

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Subcutaneous Daratumumab Offers Convenience for Patients With Multiple Myeloma

June 21st 2020

Nearly 5 years after its approval for patients with multiple myeloma, daratumumab is now available in a formulation that can be administered in a fraction of the time required with the original agent.

Dr. Lonial on Emerging Concepts in Multiple Myeloma Treatment

June 17th 2020

Sagar Lonial, MD, FACP, discusses some of the remaining challenges to address in the multiple myeloma space.

Dr. Branagan on Novel Induction Therapies With Transplant in Myeloma

June 16th 2020

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

June 15th 2020

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

June 11th 2020

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

June 10th 2020

James Weitzman, MD, discusses sequencing challenges in multiple myeloma treatment.

Dr. Davies on Personalizing Treatment in Relapsed/Refractory Myeloma

June 9th 2020

Faith E. Davies, MD, shares advice on how to best treat patients with relapsed/refractory multiple myeloma.

Dr. Mateos on the Ongoing CANOVA Trial in t(11;14) Multiple Myeloma

June 6th 2020

María-Victoria Mateos, MD, PhD, discusses the design of the ongoing phase 3 CANOVA trial in patients with relapsed/refractory t(11;14) multiple myeloma.

Dr. Dimopoulos on the Evolution of Selinexor in Multiple Myeloma

June 5th 2020

Meletios A. Dimopoulos, MD, discusses the evolution of selinexor in multiple myeloma.

Dr. Richardson on the Mechanism of Action of CC-92480 in Multiple Myeloma

June 4th 2020

Paul G. Richardson, MD, discusses the mechanism of action of CC-92480 in patients with multiple myeloma.

Subcutaneous Daratumumab Approved in Europe for Myeloma

June 4th 2020

The European Commission has approved subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma.

Dr. Lonial on the Importance of Early Intervention in High-Risk Smoldering Myeloma

June 3rd 2020

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Trial in Multiple Myeloma

June 3rd 2020

Shaji K. Kumar, MD, discusses the rate of treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Isatuximab Approved in Europe for Relapsed/Refractory Myeloma

June 2nd 2020

The European Commission has approved isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥2 prior therapies.